Is ORYZF or DGRO a better dividend investment in 2026?

ORYZF currently yields 59.88% with a 5% 5-year dividend growth rate. DGRO yields 2.13% with 9.5% growth. The better choice depends on your goal: ORYZF offers higher current income.

What is the dividend yield difference between ORYZF and DGRO?

ORYZF has a forward dividend yield of 59.88% ($2.00/share annually). DGRO yields 2.13% ($1.47/share annually). The yield gap is 57.75 percentage points.

Home › Compare › ORYZF vs DGRO

ORYZF vs DGRO: Dividend Comparison 2026

ORYZF yields 59.88% · DGRO yields 2.13%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 ORYZF wins by $616.1K in total portfolio value

INVESTMENT

TIME HORIZON10 years

ORYZF

● Live price

59.88%

Share price

$3.34

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$647.7K

Annual income

$151,154.17

Full ORYZF calculator →

DGRO

iShares Core Dividend Growth ETF

● Live price

2.13%

Share price

$68.98

Annual div

$1.47

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$31.6K

Annual income

$239.96

Full DGRO calculator →

Portfolio growth — ORYZF vs DGRO

📍 ORYZF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	ORYZF	DGRO
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, ORYZF + DGRO cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

ORYZF pays

DGRO pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ORYZF

Annual income on $10K today (after 15% tax)

$5,089.82/yr

After 10yr DRIP, annual income (after tax)

$128,481.04/yr

DGRO

Annual income on $10K today (after 15% tax)

$181.24/yr

After 10yr DRIP, annual income (after tax)

$203.97/yr

At 15% tax rate, ORYZF beats the other by $128,277.08/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ORYZF + DGRO for your $10,000?

ORYZF: 50%DGRO: 50%

100% DGRO50/50100% ORYZF

Portfolio after 10yr

$339.7K

Annual income

$75,697.07/yr

Blended yield

22.29%

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ORYZF buys

DGRO buys

No recent congressional trades found for ORYZF or DGRO in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricORYZFDGRO

Forward yield	59.88% ✓	2.13%
Annual dividend / share	$2.00 ✓	$1.47
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$647.7K ✓	$31.6K
Annual income after 10y	$151,154.17 ✓	$239.96
Total dividends collected	$536.9K ✓	$2.3K
Payment frequency	quarterly	quarterly
Sector	Stock	ETF

Year-by-year: ORYZF vs DGRO ($10,000, DRIP)

Year	ORYZF Portfolio	ORYZF Income/yr	DGRO Portfolio	DGRO Income/yr	Gap
1← crossover	$16,688	$5,988.02	$11,293	$213.22	+$5.4K → ORYZF
2	$27,195	$9,339.09	$12,730	$217.32	+$14.5K → ORYZF
3	$43,323	$14,223.60	$14,326	$221.10	+$29.0K → ORYZF
4	$67,531	$21,176.11	$16,098	$224.56	+$51.4K → ORYZF
5	$103,108	$30,849.85	$18,064	$227.74	+$85.0K → ORYZF
6	$154,347	$44,020.82	$20,246	$230.65	+$134.1K → ORYZF
7	$226,736	$61,585.45	$22,666	$233.30	+$204.1K → ORYZF
8	$327,159	$84,550.92	$25,349	$235.73	+$301.8K → ORYZF
9	$464,078	$114,017.62	$28,325	$237.94	+$435.8K → ORYZF
10	$647,717	$151,154.17	$31,624	$239.96	+$616.1K → ORYZF

ORYZF vs DGRO: Complete Analysis 2026

ORYZF — Stock

Oryzon Genomics S.A., a clinical phase biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases. The company was founded in 2000 and is based in Cornellà de Llobregat, Spain.

Full ORYZF Calculator →

DGRO — ETF

The iShares Core Dividend Growth ETF seeks to track the investment results of an index composed of U.S. equities with a history of consistently growing dividends.

Full DGRO Calculator →

📬

Get this ORYZF vs DGRO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ORYZF vs SCHD ORYZF vs JEPI ORYZF vs O ORYZF vs KO ORYZF vs MAIN ORYZF vs VIG ORYZF vs NOBL ORYZF vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.